Millipore Sigma Vibrant Logo

IM15L Anti-uPA (Ab-3) Mouse mAb (16)

Anti-uPA (Ab-3) Mouse mAb (16) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Anti-Urkinase Plasminogen Activator

View Products on Sigmaaldrich.com
IM15L
  
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information

      Key Spec Table

      Species ReactivityHostAntibody Type
      HMMonoclonal Antibody
      Description
      Overview

      This product has been discontinued.



      Recognizes uPA/PAI complexes in dexamethasone-treated HT-1080 cells and carcinoma tissue. Sold under license of U.S. Patent 5,422,245.
      Catalogue NumberIM15L
      Brand Family Calbiochem®
      SynonymsAnti-Urkinase Plasminogen Activator
      References
      ReferencesRosenquist, C., et al. 1993. Breast Cancer Res. and Treatment 28, 223.
      Foekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Product Information
      DeclarationSold under license of U.S. Patent 5,422,245.
      FormLyophilized
      FormulationLyophilized from 20 mM NH₄HCO₃, 100 µg BSA.
      Positive controlConcentrated conditioned medium from dexamethasone-treated HT-1080 cells
      PreservativeNone
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoprecipitation and Immunoblotting Rosenquist, C., et al. 1993. Breast Cancer Res. and Treatment 28, 223.
      Key Applications Immunoblotting (Western Blotting)
      Immunoprecipitation
      Application NotesImmunoblotting (2.5 µg/ml, see application references)
      Immunoprecipitation (1 µg, see application references)
      Application CommentsuPA (Ab-3) will recognize uPA in complex with PAI 1. For optimal results in immunoblotting, incubate HT 1080 cells in serum free media with 1 µM dexamethasone for 2 h and concentrate 10-20X. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenthe B chain of human urokinase plasminogen activator
      ImmunogenHuman
      Clone16
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C) for long-term storage. Avoid freeze/thaw cycles.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      IM15L 0

      Documentation

      Anti-uPA (Ab-3) Mouse mAb (16) SDS

      Title

      Safety Data Sheet (SDS) 

      Anti-uPA (Ab-3) Mouse mAb (16) Certificates of Analysis

      TitleLot Number
      IM15L

      References

      Reference overview
      Rosenquist, C., et al. 1993. Breast Cancer Res. and Treatment 28, 223.
      Foekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-August-2007 RFH
      SynonymsAnti-Urkinase Plasminogen Activator
      ApplicationImmunoblotting (2.5 µg/ml, see application references)
      Immunoprecipitation (1 µg, see application references)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells. Recognizes the B chain of uPA.
      BackgroundUrokinase-type plasminogen activator (uPA) is a serine proteinase that functions in the conversion of plasminogen to the active proteinase, plasmin1. It is secreted from cells as an inactive 52 kDa precursor (single-chain or sc-uPA) which is activated to the two-chain form consisting of an A and B-chain. The active high molecular weight form (HMW-uPA) can be further processed by removal of an amino-terminal fragment (ATF) to an active low molecular weight form (LMW-uPA) of ~33 kDa. The B-chain contains the active site and binds the two endogenous plasminogen activator inhibitors, PAI-1 and PAI-22. The binding of pro-uPA to its cell surface receptor enhances its rate of activation3. uPA is responsible for normal physiological processes such as tissue remodeling and cell migration. Since cell surface plasminogen activation is involved in extracellular matrix degradation, uPA is likely to play a key role in the process of invasion and metastasis.
      HostMouse
      Immunogen speciesHuman
      Immunogenthe B chain of human urokinase plasminogen activator
      Clone16
      IsotypeIgG₁
      Specieshuman
      Positive controlConcentrated conditioned medium from dexamethasone-treated HT-1080 cells
      FormLyophilized
      FormulationLyophilized from 20 mM NH₄HCO₃, 100 µg BSA.
      PreservativeNone
      CommentsuPA (Ab-3) will recognize uPA in complex with PAI 1. For optimal results in immunoblotting, incubate HT 1080 cells in serum free media with 1 µM dexamethasone for 2 h and concentrate 10-20X. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C) for long-term storage. Avoid freeze/thaw cycles.
      Toxicity Standard Handling
      ReferencesRosenquist, C., et al. 1993. Breast Cancer Res. and Treatment 28, 223.
      Foekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P. 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Application referencesImmunoprecipitation and Immunoblotting Rosenquist, C., et al. 1993. Breast Cancer Res. and Treatment 28, 223.